Original Article

Supportive Care in Cancer

, Volume 20, Issue 7, pp 1471-1478

First online:

Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study

  • Paul J. HeskethAffiliated withDepartment of Hematology and Oncology, Lahey Clinic Medical Center Email author 
  • , Oliver WrightAffiliated withGSK Research and Development
  • , Gerardo RosatiAffiliated withMedical Oncology Unit, S. Carlo Hospital
  • , Mark RussoAffiliated withGSK Research and Development
  • , Jeremey LevinAffiliated withGSK Research and Development
  • , Stephen LaneAffiliated withGSK Research and Development
  • , Vladimir MoiseyenkoAffiliated withPetrov Research Institute of Oncology
  • , Pierre DubeAffiliated withHôpital Maisonneuve-Rosemont, Université de Montréal
  • , Mikhail KoppAffiliated withSamara Regional Oncology Center
    • , Anatoly MakhsonAffiliated withStavropol Regional Oncology Center

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access



The primary objective was to determine if a single dose of casopitant 90 mg added to ondansetron and dexamethasone would improve the control of chemotherapy-induced nausea and vomiting (CINV) over 0–120 h following initiation of oxaliplatin-based moderately emetic chemotherapy (MEC) compared to ondansetron and dexamethasone alone.


Patients with colorectal cancer received either casopitant or placebo intravenously (IV) added to ondansetron 8 mg bid oral on study days 1 to 3 and one dose of dexamethasone 8 mg IV given prior to starting the oxaliplatin on day 1. The primary endpoint was the percentage of subjects achieving complete response (CR; no vomiting/retching or use of rescue medication) during 120 h after initiation of chemotherapy in cycle 1.


No difference in the rate of CR was noted in the casopitant group compared to the placebo group for the overall (placebo 85%, casopitant 86%, p = 0.7273), acute (placebo 96%, casopitant 97%), or delayed phases (placebo 85%, casopitant 86%). The average area under curve (0–) of casopitant after a single 90-mg IV dose was 8,390 ng h/mL. At 24 h after casopitant 90-mg IV dosing, the plasma casopitant concentration was 24% lower than the values noted in prior studies with 150 mg oral administration, and the plasma exposure of the major metabolite (GSK525060) was 18% lower.


Addition of single-dose casopitant 90 mg IV did not improve the control of CINV at any time during 120 h following initiation of oxaliplatin-based MEC. Excellent control of CINV was achieved in this study population with the combination of ondansetron and dexamethasone alone.


CINV Pharmacokinetics Acute nausea and vomiting Delayed nausea and vomiting MEC